NasdaqGS:NVAXBiotechs
Novavax (NVAX): Rethinking Valuation Following Debt Refinancing and Enhanced Financial Flexibility
Novavax (NVAX) just adjusted its balance sheet in a way that could change how investors view the company's prospects for the next few years. The company has completed a sizable refinancing by issuing $225 million in convertible senior notes due 2031. This transaction extends most of Novavax’s debt obligations by several years, lowers the interest rate, and frees up near-term cash flow. For investors considering NVAX, this move signals management’s confidence and prompts a fresh evaluation of...